Redcare Pharmacy N.V. (ETR:RDC) on Monday said third-quarter prescription sales in Germany surged 82% year over year to €126 million, lifting total group revenue 25% to €719 million.
The online pharmacy operator reaffirmed its full-year guidance following broad growth across both prescription and non-prescription categories.
The Netherlands-based company said total prescription, or Rx, sales rose 42.3% to €272 million from €191 million a year earlier, while non-prescription, or non-Rx, sales increased 16.7% to €448 million.
Year to date, total revenue climbed 27% to €2.15 billion, up €450 million from the prior-year period.
Both of Redcare’s reporting segments recorded double-digit growth. Revenue in the DACH region, covering Germany, Austria and Switzerland, rose 25.2% to €587 million from €469 million.
Within that segment, non-Rx sales grew 13.4% to €315 million, and Rx sales advanced 42.3% to €272 million. The company reported that year-to-date revenue in the DACH region reached €1.74 billion, up 26.7%.
Sales in the International segment, which includes Belgium, Italy, France and the Netherlands, rose 25.4% to €132 million from €105 million. Year-to-date revenue for the segment totaled €402 million, an increase of 25.9%.
At the end of the third quarter, Redcare said it had 13.7 million active customers, an increase of 200,000 since the previous quarter.
The company’s net promoter score, a measure of customer satisfaction, improved to well over 70, up from 64 recorded in the first half of 2025.
“We are delivering strong Q3 momentum, especially in German Rx where we grew double-digits quarter over quarter, and confirm full-year guidance,” Chief executive officer Olaf Heinrich said in a statement.
“Growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%,” Heinrich added.
Redcare said it expects to reach at least €500 million in prescription sales for the full year, supported by the continued expansion of its German Rx business and seasonal increases in order volumes during the final quarter. The company reaffirmed all elements of its full-year guidance.
Management said financial operations remain stable during the current transition period and that continuity is ensured until the appointment of a new chief financial officer.
Source :
https://www.investing.com/news/earnings/redcare-pharmacy-q3-sales-jump-25-as-german-rx-revenue-soars-82-4271540
